Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Belite Bio, Inc - American Depositary Shares (NQ: BLTE )

49.50 +0.74 (+1.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,757
Open 49.46
Bid (Size) 46.81 (1)
Ask (Size) 50.05 (1)
Prev. Close 48.76
Today's Range 48.50 - 49.83
52wk Range 20.32 - 50.66
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Belite Bio to Present at the JonesHealthcare Seaside Summit
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
From Belite Bio, Inc
Via GlobeNewswire

Performance

YTD
+15.76%
+15.76%
1 Month
+8.03%
+8.03%
3 Month
+21.92%
+21.92%
6 Month
+11.74%
+11.74%
1 Year
+113.18%
+113.18%

More News

Read More
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
From Belite Bio, Inc
Via GlobeNewswire
Expert Ratings for Belite Bio
Via Benzinga
BLTE Stock Earnings: Belite Bio Misses EPS for Q1 2024
Via InvestorPlace
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Announces $25 Million Registered Direct Offering
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio to Participate in the BTIG Ophthalmology Day
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio, Inc. to present at the Deutsche Bank ADR Virtual Investor Conference on 8 November 2023
From Virtual Investor Conferences
Via GlobeNewswire
Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting
From Belite Bio, Inc
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.